News Release Detail
Mylan Receives Approval for Tramadol Hydrochloride Tablets
Mylan's Tramadol product is the generic version of R.W. Johnson Pharmaceutical Research Institute's Ultram® Tablets which is indicated for the management of moderate to moderately severe pain.
Mylan Laboratories Inc., is a leading pharmaceutical company that develops, manufacturers and markets generic and proprietary prescription pharmaceutical products. The company markets an extensive line of generic products through three business units, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., and UDL Laboratories, Inc. and branded products through Bertek Pharmaceuticals Inc. For more information, visit www.mylan.com.
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking statements regarding our anticipated financial results and estimates, business prospects and products in research and under going development, all of which involve substantial risks and uncertainties. Such risks and uncertainties are not predictable or quantifiable; consequently, should known or unknown risks or uncertainties materialize, or should our assumptions or estimates prove inaccurate, actual results could differ materially from those expressed or implied by such forward-looking statement. For further details and a discussion of such risks and uncertainties, we encourage you to read Forward-looking Statements found in our Annual Report on Form 10-K for the fiscal year ended March 31, 2001, and in our periodic reports on Forms 10-Q and 8-K (if any).
We assume no obligation to update any forward-looking statements presented here today, whether as a result of new information, future events or otherwise.
CONTACT: Mylan Laboratories Inc.
Patricia Sunseri, 412/232-0100
URL: http://www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2002 Business Wire. All rights reserved.